Cytovance Biologics and Akshaya Bio Announce Collaboration Agreement of Therapeutics for Treatment of Coronavirus and Hepatitis B Virus Infections
23 avr. 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, April 23, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink...
Cytovance Biologics Promotes Dr. Jesse McCool to Chief Executive Officer
30 mars 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Jesse...
Cytovance® Biologics Introduces an Integrated Single-use Platform for Plasmid DNA (pDNA) Manufacture
21 oct. 2019 12h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Cytovance Biologics is a leading biopharmaceutical CDMO with a 15-year track record of supplying drug substance to clients, offering fast and...
Cytovance Biologics to Participate in RAFT Scientific Discussion on Commercialization of Fermentation Processes
18 oct. 2019 17h24 HE
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
Cytovance Biologics to Participate in Boston’s BioProcess International Convention
30 août 2019 08h10 HE
|
Cytovance Biologics
OKLAHOMA CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
Cytovance® Biologics Inc. appoints Dr. Jesse McCool as Chief Technology Officer
27 juin 2019 10h38 HE
|
Cytovance Biologics
Cytovance® Biologics Inc. announced that Dr. Jesse McCool will serve the company as CTO, effective June 27, 2019 OKLAHOMA CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading...
Cytovance® Biologics Inc., Completes Its Second FDA Pre-Approval Inspection (PAI) of Oklahoma City, OK Facilities
14 juin 2019 12h15 HE
|
Cytovance Biologics
OKLAHOMA CITY, June 14, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics announced that it has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug...
Cytovance® Biologics Promotes Matt Hamilton to Vice President, Finance
23 avr. 2019 10h57 HE
|
Cytovance Biologics
OKLAHOMA CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, has promoted Matt...
Cytovance Biologics Congratulates Siwa Biotech on Commercial Medical Device Approval
29 mars 2019 11h32 HE
|
Cytovance Biologics
OKLAHOMA CITY, March 29, 2019 (GLOBE NEWSWIRE) -- Cytovance Biologics announces Siwa Biotech’s receipt of FDA licensure of Anti-Fya and Anti-Fyb recombinant monoclonal Blood Grouping Reagents. These...
Horizon Discovery enters into license agreement with Cytovance Biologics for HD-BIOP3 Suspension adapted GS null CHO K1 cells
03 oct. 2018 05h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, Okla., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc. signed a non-exclusive license with Horizon Discovery for the use of their HD-BIOP3 Suspension adapted GS null CHO...